www.byzcath.org Forums News & Events Church News Beauty salons fuel trade in aborted babies

Racketeers pay Ukraine women to sell foetuses to quack clinics for �10,000 courses of 'anti-ageing' jabs

from The Observer [observer.guardian.co.uk]
LORD HAVE MERCY!

SSSSSSSIIIIIIICCCCCCCKKKKKKK!!!!!!!

Many of the cosmetics used here in the states have part of that for years. I was praying at a clinic once when they came to pick up the fetuses. So I don't use them at all. This lets one see some of the uses. THIS IS NOT FOR THE WEAK OF HEART. No picuters just words, very discriptive though.
http://www.skepticfiles.org/mys2/deadbaby.htm

My daughter has been trying to tell me for years that certain beauty products were made from aborted babies. I didn't believe her because I didn't want to believe that something so horrible could be true. I owe that child an apology. Thank God that I tried to 'humor' her and didn't buy the products that she asked me not to buy.

Vie

I want a little more proof than this. When I consider the volume of aborted babies against the volume of cosmetics sold, something doesn't add up. I don't doubt anyone's sincerity in posting this, but it does seem to resemble an urban legend.

Some Documented Experiments on Aborted Babies.

* At Stanford University, living aborted babies were placed in incubators. Their chests were cut open so that researchers could observe their heart actions. The babies died within 11 hours. American Journal of Obstetrics and Gynecology, July 1, 1963.
* Researchers at the University of Colorado used 114 aborted babies for experiments on the lower jaw. American Journal of Anatomy, 1971.
* In California, thymus glands obtained from aborted babies have been transplanted into older children. Time Magazine, Feb. 28, 1972.
* In 1974 an experiment involved cutting the beating hearts out of aborted babies and placing them in a nutrient solution. "The hearts survived for many hours without any significant change in their spontaneous contraction rate." American Journal of Obstetrics and Gynecology, January 1, 1974.
* Researchers at the Children's Hospital in Helsinki, Finland, experimented on 12 babies from 12 to 21 weeks gestation, killed by hysterotomy. The babies' heads were cut off and attached to a machine that pumped chemicals through the severed brains. Acta Paedriatrica, Scandinavia, January 1975.
* The U.S. Environmental Protection Agency approved a $300,000 project which used 100 aborted babies to test the effects of pesticides. Chicago Sun Times, July 26, 1977.
* In April, 1981, guards at the Swiss-French border intercepted a truck loaded with frozen human fetus' destined for French cosmetic laboratories. Gazette du Palais, 1981.
http://actionlife.org/content/view/63/208/

There are thus possibilities for abuse about which even the more moderate advocates are wary. Already there have been people not simply willing but eager to conceive just to donate the tissue. [45] Fetal tissue is currently being used to make cosmetics in Sweden, and fetal kidneys from Brazil and India are being sold in West Germany to physicians for transplant. [46] It is true that most advocates recommend some laws or voluntary guidelines to keep such abuses from taking place. These may be adequate for the short run, but there are no guarantees that these kinds of abuses can be prevented in the long run as the process becomes more acceptable. This opposition to the transplants is not "burning down the barn to roast the pig," but rather, stopping the descent down the slippery slope at the top. It is naive to think that the long-run pressure can be resisted, given the powerful incentives to donate the tissue that the advances in medical science promise to provide.

The footnotes are with the whole article http://www.iclnet.org/pub/resources/text/cri/cri-jrnl/web/crj0145a.html

DON'T BLIND YOURSELF TO THINKING THIS IS AN URBAN LEGEND! SATAN IS A GROSS BEING AND WILL STOP AT NOTHING TO GET THE SOULS OF HUMANS.

What better way than to go against what Isaiah 49:15 Can a mother forget her infant, be without tenderness for the child of her womb? Even should she forget, I will never forget you.

But God says to that child that is so forsaken by it's mother in Isaiah 49:16

See, upon the palms of my hands I have written your name; your walls are ever before me.

I don't doubt the medical experiments, it's the widespread use of aborted babies in cosmetics that I question. Those Suave products I buy are already dirt cheap, so it wouldn't be economical for the manufacturer to use baby parts in them. Again, the cosmetics industry is huge. I question whether there are enough aborted babies to go around for that purpose. Now granted, there could very well be some high-end, expensive cosmetics that could use baby materials. But the over the counter stuff at Walgreens - it wouldn't be economical.

The beauty industry has been using human placenta in many of its "high end" consmetics since the 1940s. It also uses amniotic fluid. I have not noticed anything concerning tissue from fetuses, but then, I have never looked.

Gaudior, offering this article to Charles, and shaking head over the things some women do...

FDA- Cosmetic Ingredients: Understanding the Puffery

by Judith E. Foulke FDA

U.S. Food and Drug Administration
FDA Consumer magazine
May 1992
Table of Contents

The lotion contained bovine albumin and the label claimed it would give a "face lift without surgery." The Food and Drug Administration said the claims caused the product to be a misbranded drug. In 1968, the court said no. "If lifting and firming products are deemed intended to affect the structure of the body, girdles and brassieres must be devices within the meaning of the law."

In 1969 an appellate court overturned this decision, but the issues persist today. "Most cosmetics contain ingredients that are promoted with exaggerated claims of beauty or long-lasting effects to create an image," says John E. Bailey, Ph.D., director of FDA's division of color and cosmetics. "Image is what the cosmetic industry sells through its products, and it's up to the consumer to believe it or not," Bailey says.

In the past, cosmetic manufacturers have depended upon mysterious "gimmick" additives, such as turtle oil to promote skin rejuvenation or tighten chin muscles, shark oil, queen bee royal jelly, chick embryo extract, horse blood serum, and pigskin extracts.

Promotion of these "gimmick" additives, combined with today's more sophisticated cosmetic ingredients, is what Bailey and the cosmetic industry call "puffery."

The argument is sometimes made that while Congress intended to safeguard the health and economic interests of consumers with the Federal Food, Drug, and Cosmetic Act, it also meant to protect a manufacturer's right to market a product free of excessive government regulation. And, in an industry that sells personal image, especially images of beauty and sex appeal, not allowing the puffery claims would certainly hurt the marketing, says Bailey.

But there's hope for credibility in claims for cosmetic ingredients. Some of the more responsible cosmetic firms are rethinking their claims that push believability to its outside edge. Linda Allen Schoen of Neutrogena says that today's more knowledgeable consumer wants "facts versus puffery--products based on skin care realities, promises banked on achievable benefits." Besides, says Schoen, limited recession dollars tend to be spent on products consumers can trust.

Still, with the exception of colors and certain prohibited ingredients, a cosmetic manufacturer may use essentially any raw material in a product and market it without prior FDA approval. The prohibited ingredients are biothionol, hexachlorophene, mercury compounds (except as preservatives in eye cosmetics), vinyl chloride and zirconium salts in aerosol products, halogenated salicylanilides, chloroform, and methylene chloride.

Federal regulations require ingredients to be listed on product labels in descending order by quantity, but often the list is not user-friendly. Because cosmetic ingredients are often complex chemical substances, the list may be incomprehensible to the product's average user. (See "Cosmetic Safety: More Complex Than at First Blush" in the November 1991 FDA Consumer.) However, if the same name is used by all manufacturers, consumers can compare different products and make reasonable value judgments.

Although cosmetic claims, even those considered "puffery," are allowed without scientific substantiation, if a cosmetic makes a medical claim, such as removing dandruff, the product is regulated as an over-the-counter drug for which scientific studies demonstrating safety and effectiveness must be submitted to FDA.

Baffling Names

Because of the unusual and sometimes bewildering nature of some ingredients in cosmetics, consumers often ask FDA for explanations. "My night cream contains liposomes--what is that?" "Why is placenta used in cosmetics--is it human placenta, and could I get a disease from it?" "What are cerebrosides and ceremides?"

FDA cosmetic scientists can explain the nature of an ingredient when it is identified by its chemical name. But when an ingredient is listed by its trade name, FDA usually must consult the manufacturer's trade literature or the International Cosmetic Ingredient Dictionary, published by the Cosmetic, Toiletry, and Fragrance Association, Inc., the industry's major trade association. The dictionary, now in its fourth edition, provides a uniform system for assigning ingredient names. FDA currently recognizes the second edition as a primary reference.

Here is what FDA knows about some currently marketed ingredients:

Liposomes are microscopic sacs, or spheres, manufactured from a variety of fatty substances, including phospholipids. While phospholipids are natural components of cell membranes, the material actually used in cosmetics may be obtained either from natural or synthetic sources. When properly mixed with water, phospholipids form liposome spheres, which can "trap" any substance that will dissolve in water or oil.

Manufacturers say that liposomes act like a delivery system. They claim that, when present in a cream or lotion, liposomes can more easily penetrate the surface skin to underlying layers, "melt," and deposit other ingredients of the product.

Nayad is a trade name for yeast extract. The manufacturer's literature describes Nayad as a "new system that takes yeast cells and refines them hundreds of times.... What results is a highly concentrated, odor-free, unusually potent yeast extract ...." The same literature reports that "no one really knows how Nayad is working in the skin; all we know for certain is the way it makes the skin look and feel. Test subjects report a noticeable smoothing of lines and wrinkles." FDA has no data to either substantiate or refute these claims.

Vitamins are added to cosmetics by manufacturers because foods containing vitamins A, D, E, K, and some of the B complex group are necessary in diets to maintain healthy skin and hair. Using these vitamins in cosmetics that are applied to the skin surface implies that skin will be nourished by them.

But Stanley R. Milstein, Ph.D., associate director for FDA's cosmetics division, says the notion that skin can be nourished by a vitamin applied to its surface has not been proven clinically. For that reason, says Milstein, a vitamin added to a cosmetic product must be listed in the ingredient label by its chemical name so that it doesn't convey a misleading message. However, FDA does not prohibit listing vitamins by their common names on the principal display panel of a cosmetic as long as the consumer is not misled and no therapeutic claims are made.

Some leaders in the cosmetic industry, such as Neutrogena's Schoen, agree with the FDA position on vitamins in skin care products. Others, such as Chris Vaughn of Sun Pharmaceuticals, Ltd., cite clinical studies done by Hoffmann-La Roche and others that show that vitamins can penetrate layers of skin and have beneficial effects. This, however, would make it a drug use, and manufacturers who use vitamins in their products don't usually make claims that would cause their products to be classified as drugs. Vaughn says that getting a drug classification is time-consuming and expensive, and in his opinion not justifiable because the informed consumer understands the beneficial properties of vitamins.

Although the debate about the value of vitamins in skin care products continues, it is generally accepted that a sufficient quantity of vitamin E (shown on ingredient lists as tocopherol), an antioxidant, preserves the fatty components in cosmetic creams and lotions to prevent off-color and off-odors.

Aloe vera is a plant from the lily family whose anti-irritant properties have been recognized since before the days of Cleopatra. It is listed as an ingredient in many skin lotions, but it would take much more aloe vera than most products contain for the anti-irritant properties to work.

Milstein explains that aloe vera, as a cosmetic ingredient, is expensive because it requires delicate processing and handling. A product that contains the 5 to 10 percent aloe vera necessary for the anti-irritant properties to be effective would send the price out of range for many consumers.

What About Biological Ingredients?

A number of biological products in cosmetics have raised consumer concern:

Human placenta is the nourishing lining of the womb (uterus), which is expelled after birth. When placental materials were first used as cosmetic ingredients in the 1940s, manufacturers promoted the products as providing beneficial hormonal effects such as stimulating tissue growth and removing wrinkles. (Although newborn infants emerge from the womb with wrinkled skin!) The hormone content and the tissue-growth and wrinkle-removing claims classified the placenta-containing products as drugs, and FDA declared them to be ineffective and therefore misbranded.

FDA's challenge caused placenta suppliers to change marketing strategies by claiming that hormones in their placenta ingredients had been extracted and were no longer in the product. They then offered placental raw materials without medical claims--only as a source of protein.

Can you get a disease from placental cosmetic ingredients? Bailey says no. Placenta used in cosmetics is washed and processed many times to destroy any harmful bacteria or viruses. Besides that, says Bailey, the cosmetic matrix (components that bind the ingredients in products) is made from a wide variety of substances, such as alcohol and preservatives, that would present a hostile environment to any viruses or bacteria the placenta might have carried.

Amniotic liquid (from cow or ox) is the fluid that surrounds the developing fetus and protects it from physical injury. It is promoted for benefits similar to those of human placenta and has limited use in moisturizers, hair lotions, scalp treatments, and shampoos.

Collagen (from young cows) is the protein substance found in connective tissue. (Connective tissue binds together and supports organs and other body structures.) A great deal of research has been done on the different types and uses for collagen. In cosmetics, collagen has a moisturizing effect. It is not water soluble, but it holds water. FDA says there is no convincing evidence that collagen can penetrate the skin and have an effect below the surface.

Cerebrosides (from animals or plants) are a type of glycolipid (a chemically combined form of fatty substance and carbohydrate) produced naturally in basal epidermal cells--the deepest layer of skin. After cerebrosides are formed, they are secreted to the outside of the cells and serve as a protective coating. As new cells form in lower layers of skin, the older skin cells move closer to surface layers and start to dry out. During this process, the cerebrosides are chemically changed and form ceramides, part of a network of membranes between cells. Skin moisture and suppleness comes from this network.

The raw material for cerebrosides in cosmetics comes from cattle, oxen or swine brain cells or other nervous system tissues. Alternatively, the raw material may be isolated from plant sources. Industry cosmetic scientists claim that the use of cerebrosides in skin products results in a smoother skin surface and better moisture retention, effects that translate into marketing claims such as luminosity and ever-improving hydration. FDA has not evaluated the studies on which these claims are based.

Industry Self-Regulation

"The cosmetic industry is sensitive to the image of an uncontrolled market where anything goes," says Bailey. "They counter this image with well-established self-regulation programs. Part of the incentive for such industry policy is to avoid increased regulatory authority."

The most well-known of industry-sponsored self-regulation is the Cosmetic Ingredient Review, sponsored by the Cosmetic Toiletry and Fragrance Association. The CIR is accomplished by a panel of scientific and medical experts who evaluate cosmetic ingredients for safety and publish detailed reviews of available safety data. "A finding of safety by the CIR provides a degree of confidence that the ingredient can safely be used in cosmetics," Bailey says. "In the absence of the CIR program, there would be no systematic examination of the safety of individual cosmetic ingredients." FDA has no statutory authority to require that the data be submitted to the agency.

FDA encourages industry cooperation through its cosmetic voluntary reporting program. Cosmetic firms registered in the program voluntarily report manufacturing and formulation information, along with product experience data, to FDA. Adverse reactions such as skin irritations are also reported. Using this information, FDA can determine a baseline reaction rate for specific product categories such as hair coloring or eye makeup preparations. The agency gives participating companies this baseline information so they can compare their own adverse reaction rates to the FDA-established baseline.

"Registration in this voluntary program does not mean that FDA approves or endorses a firm, raw material, or product," says Mary Waleski, chief of the cosmetic registration program. "But it does provide for an interaction between the industry and government for exchange of information."

FDA would like to see wider industry participation. "Based on the number of companies we think are eligible to participate, only about 35 percent do," Waleski says. There are also other problems. "Sometimes the information a firm submits is incomplete," Waleski says. "And if a firm does not update its submissions with additions or deletions, the information in the registration files could accumulate as inaccurate information."

FDA continues to explore ways to make the program more useful for both industry and government, says Bailey. "We compare product information available to the agency with registered data, and now we're considering periodic field surveys of products on the shelves. Such a review would include comparison of label ingredient declarations with information reported to FDA."

The quest for sustained youth and beauty that sells cosmetics is age-old, though ingredients used to achieve that image may change. Shakespeare noted the same concern that keeps the cosmetic industry going when he said,


Time doth transfix the flourish set on youth
And delves the parallels in beauty's brow.

But he gave voice to another standard when he wrote,

To me, fair friend, you never can be old,
For as you were when first your eye I eyed,
Such seems your beauty still.

Judith Foulke is a staff writer for FDA Consumer.
Publication No. (FDA) 95-5013

I never knew this was going on!

We must become more vigilit with our PRO-LIFE ministry! This evil must not be allowed to continue! This is much worse than any Holocaust.

I am tears thinking about it. Only God can help us!

The only appropriate Scripture that comes to mind:

I agree, Gaudior, but it's the things women and men do these days. I have read that some were concerned about ceramides because of the link between mad cow disease and the nerve and brain tissue from which it is made. Like I said, I will stick with Suave. It's got cheap stuff in it - which is probably better for me anyway.

Can anyone recommend websites of serious journalism into the whole question of the use of the remains of aborted babies? Over time, I have read all kinds of fantastic claims --babies' body parts sold for medical research, for organ transplants, for vaccines, etc. Usually when I try to research these claims, I find a lot of hyperbole but little evidence and facts. The article from The Observer seems to be solid journalism. Are there any other reports of serious quality available?

--John

Here are the footnotes from the last article I used a quote from, it is a very serious writing. You should be able to get resources from it. The authors name also follows..
About the Author

Scott B. Rae is Assistant Professor of Bible Exposition at Talbot School of Theology, La Mirada, California. A Graduate of Dallas Theological Seminary, he is currently a Ph.D. candidate in social ethics at the University of Southern California.

Notes

1 "Denver Hospital Defies Ban on Fetal Tissue Transplant," Medical Ethics Advisor 4 (December 1988):161. See also Andrew Simons, "Brave New Harvest," Christianity Today, 19 November 1990, 24-25.
2 Quoted by Richard John Neuhaus, "The Return of Eugenics," Commentary 85 (April 1988):18.
3 Statement made in testimony before the NIH Panel, 15 September 1988, and contained in the Report of the Human Fetal Tissue Transplantation Research Panel (hereafter RHFTTRP), vol. 2, D68.
4 Statement made by Robin Chandler Duke, in testimony to the NIH Panel and contained in the RHFTTRP, vol. 2, D114.
5 A helpful summary of the scientific advantages of fetal tissue for some of these transplants is Robert Auerbach and Harold R. Wolfe, RHFTTRP, vol. 2, D28-D31.
6 The medical discussion of Parkinson's disease is taken from Alan Fine, "The Ethics of Fetal Tissue Transplants," Hastings Center Report 18 (June/July 1988):5.
7 Christopher M. DeGiorgio, "Medical and Selected Ethical Aspects of Fetal Tissue Transplantation," Critical Issues in Health Care (1989):2.
8 Fine, 6.
9 James Bopp and James Burtchaell, "Fetal Tissue Transplantation: The Fetus as Medical Commodity," This World 26 (Summer 1989): 67-68.
10 Henry T. Greely, et al., "The Ethical Use of Human Fetal Tissue in Medicine," New England Journal of Medicine 320 (20 April 1989):1093.
11 I. Medrazo, R. Drucker-Colin, V. Leon, and C. Torres, "Open Microsurgical Autograft of Adrenal Medulla to the Right Caudate Nucleus in Two Patients with Intractable Parkinson's Disease," New England Journal of Medicine 316 (1987):831-34.
12 DeGiorgio, 3.
13 Edwin Kiester, Jr., "Spare Parts for Damaged Brains," Science 86 (March 1986):47-56.
14 Steven McLoon and Raymond Lund, "Development of Fetal Retina, Tectum and Cortex Transplanted to the Superior Colliculus of Adult Rats," Journal of Comparative Neurology 217 (1983):376-89.
15 Walter Sullivan, "Cell Implants Curb Parkinson's in Two Monkeys," New York Times, 17 May 1986, 1.
16 Rick Weiss, "Fetal Cell Transplants Show Little Promise," Science News 134 (1988):324.
17 Ibid.
18 John R. Sladek and Ira Shoulson, "Neural Transplantation: A Call for Patience Rather than Patients," Science 240 (10 June 1988):1387.
19 Kathleen Nolan, "Genug Ist Genug: A Fetus Is Not a Kidney," Hastings Center Report 18 (December 1988):13.
20 Mildred Washington, "Fetal Research: A Survey of State Law," Congressional Research Service Report for Congress (8 March 1988):1.
21 John A. Robertson, "Rights, Symbolism and Public Policy in Fetal Tissue Transplants," Hastings Center Report 18 (December 1988):5.
22 Ibid., 12, note 37. The statute in Louisiana has been successfully challenged on constitutional grounds that it restricts the woman's right to an abortion guaranteed under Roe v. Wade. It is unclear, however, whether the law actually restricts the right to an abortion or the right to designate a recipient of the fetal tissue. It appears that the challenge assumed that the fetus was the right of the mother to dispose of as she wished.
23 Ibid., 12, note 28. These states include Arkansas, Illinois, Ohio, Louisiana, Oklahoma, Florida, Massachusetts, Maine, Michigan, Minnesota, North Dakota, Nevada, Rhode Island, Tennessee, Texas, Pennsylvania, and Wyoming.
24 Consultants to the Advisory Committee to the Director, National Institutes of Health, RHFTTRP, (December 1988):vol. 2, A25.
25 This position appears in the writing of John A. Robertson in two principal articles: "Fetal Tissue Transplants," Washington University Law Quarterly 66 (1988):443-98; and "Rights, Symbolism, and Public Policy in Fetal Tissue Transplants," Hastings Center Report 18 (December 1988):5-12.
26 The intent of the family to conceive solely for the bone marrow donor is underscored by the fact that the father underwent surgery to reverse a vasectomy six months prior to conception of the child who will be the donor. See Orange County Register, Sect. B, 31 August 1990. The bone marrow transplant was performed in May, 1991.
27 This position is represented by James Bopp, Esq. and Father James Burtchaell in their dissent from the majority opinion of the NIH Panel. See Bopp and Burtchaell, 54-79.
28 Billy S. Arant, Jr., "Why the Government Should Lift the Moratorium," Christianity Today, 19 November 1990, 28.
29 Ibid.
30 LeRoy Walters, "Ethical Issues in Experimentation on the Human Fetus," Journal of Religious Ethics 2 (Spring 1974):41, 48.
31 Paul Ramsey, The Ethics of Fetal Research (New Haven: Yale University Press, 1975):89.
32 Bopp and Burtchaell, 59.
33 This point is made by Nolan, 14. The reference to Mahowald and team is taken from Mary B. Mahowald, Jerry Silver, and Robert A. Ratcheson, "The Ethical Options in Transplanting Fetal Tissue," Hastings Center Report 17 (February 1987):9-15.
34 Stuart A. Newman, "Statement on Proposed Uses of Human Fetal Tissue," Panel Report, vol. 2, D207.
35 Nolan, 18.
36 Mahowald, et al., 12, 15.
37 Nolan, 16.
38 Karen Southwick, "Fetal Tissue Market Draws Profits, Rebuke," Health Week, 12 October 1987, 1.
39 Moore v. Regents of the University of California, California Court of Appeal, 249 Cal. Rptr. 494 (1988). Review granted by California Supreme Court, 252 Cal. Rptr. 816 (10 November 1988).
40 Mahowald, et al., 7-15.
41 Nolan, 17.
42 "Concern that the use of fetal tissue for transplantation in such cases could become an incentive for abortion thus appears well grounded." Fine, 6.
43 Michael Bracken, Lorraine Klerman, and Mary Ann Bracken, "Abortion, Adoption or Motherhood: An Empirical Study of Decision-Making During Pregnancy," American Journal of Obstetrics and Gynecology 130 (1978):256-57.
44 Bopp and Burtchaell, 67.
45 Tamar Lewin, "Medical Use of Fetal Tissue Spurs New Abortion Debate," New York Times, 16 August 1987, 1.
46 Debra McKenzie, "Third World Kidneys for Sale," New Scientist, 28 March 1985, 7; "Embryos to Lipsticks?" New Scientist, 10 October 1985, 21.
47 For the use of fetal pancreatic cells in the treatment of diabetes, see the Panel Report, vol. 2, D255. For the use of neuroblastoma cells, see 12.
48 Panel Report, vol. 2, E15.
49 Cited in the Panel Report, vol. 2, D101. See also David Dickson, "Fetal Tissue Transplants Win U.K. Approval," Science 245 (4 August 1989):464-65.

In England

The use of fetuses

13 In the UK there are no specific statutory provisions governing the use that can be made of tissues from the cadavers of fetuses, although the Abortion Act (1967) governs the legality of the abortion which makes fetal tissue available. Any subsequent use of fetal tissue was considered in 1989 by the Polkinghorne Committee which reviewed the guidance on the research use of fetuses and fetal material and recommended a code of practice.(14) The uses of fetal tissue contemplated in the Review included teaching, therapy and research. The Polkinghorne Review concluded that 'ethics committees should examine all proposals for work with fetuses or fetal tissue, whether alive or dead, and whether classed as research or therapy, because of the high level of public concern'. Research ethics committees in the UK have already approved research on the technique of transplanting cadaveric fetal tissue into the brains of those affected with Parkinson's disease.
http://www.nuffieldbioethics.org/go/browseablepublications/stemcells/report_510.html
http://www.prochoiceforum.org.uk/comm66.asp

Notes

1.Coutts, Mary Carrington, "Fetal Tissue Research," Kennedy Institute of Ethics Journal, Vol. 3, #1, pp. 81-101.

2.Johnson, Walter, M.D., "Don't Be Lulled: Live Fetuses Used in Tissue Transplants," New Earth, 5/93, p. 14. Further reading:
(A) Haskell, Martin, M.D., "Second Trimester D and X, 20 Wks and Beyond," National Abortion Federation presentation, 10/92, 10 pages;
(B) Hutchinson, Robert, "Fetal Harvesting Insan- ity," You! 5/93, pp. 20-23 complete with graphic drawings of how the baby's brain cells are extracted prior to the completion of the abortion.

3.Wikler, Daniel, and Barondess, Jeremiah, "Bioethics and Anti-Bioethics in Light of Nazi Medicine: What Must We Remember?" Kennedy Institute of Ethics Journal, Vol. 3, #1, pp. 39-55.

4.Fleck, Fiona, "Russians Start Human Foetal Tissue Transplant Operations," Reuters News Service, 3/20/93, #2115.

5."Human Fetal Tissue Transplantation Treatment for Diabetes (DM), Parkinson's, Alzheimer's Disease Available to U.S. Patients in Moscow," PR Newswire, 9/24/92.

6."Fetal Tissue: Moscow Clinic and U.S. Doc Enter Partnership," Abortion Report, 5/18/93, p. 10.

7.Marshall, Hon. Robert, "Excerpts, Summary and Analysis of 'The Use of Human Fetal Tissue: Scientific, Ethical and Policy Concerns,'" prepared by American Life League, 1992.

8.Ibid.

9.Huston, James W., "Fetal-Tissue Implants: An Ethical E-ticket Ride," San Diego Union-Tribune, 4/27/92.

10.White, Robert J., M.D., "Fetal Brain Transplantation: Questionable Human Experiment," America, 11/28/92, pp. 421-22.

11.Nathanson, Bernard, M.D., "Fetal Tissue Research and Experimentation," ALL About Issues, 3-4/92, pp. 33-34.

12.Smith, Senator Robert, "There Is a Moral Line We Cannot Cross When It Comes to Fetal Tissue Research," Roll Call, 5/21/92, pp. 33-34.

13.Wikler and Barondess, op. cit., p. 47, quoting By Trust Betrayed, by Hugh Gallagher.

14.1/6/93 letter from Dr. Fahn to Ms. Mary Barron.
RECOMMENDED READING:

LeJeune, Jerome, M.D., The Concentration Can, Ignatius Press

Rini, Suzanne, Beyond Abortion: A Chronicle of Fetal Experimentation
http://www.all.org/issues/eg99y.htm